ITTO20020340A0 - Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato. - Google Patents
Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato.Info
- Publication number
- ITTO20020340A0 ITTO20020340A0 IT2002TO000340A ITTO20020340A ITTO20020340A0 IT TO20020340 A0 ITTO20020340 A0 IT TO20020340A0 IT 2002TO000340 A IT2002TO000340 A IT 2002TO000340A IT TO20020340 A ITTO20020340 A IT TO20020340A IT TO20020340 A0 ITTO20020340 A0 IT TO20020340A0
- Authority
- IT
- Italy
- Prior art keywords
- humanized
- localization
- biotinylated antibody
- her2 receptor
- her2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
- A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medical Informatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2002TO000340A ITTO20020340A1 (it) | 2002-04-19 | 2002-04-19 | Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato. |
| EP03008916A EP1357132A3 (en) | 2002-04-19 | 2003-04-16 | Detection of the her2 receptor by means of biotinylated humanized antibody |
| US10/417,336 US20040110239A1 (en) | 2002-04-19 | 2003-04-17 | Detection to the HER2 receptor by means of biotinilated humanized antibody |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2002TO000340A ITTO20020340A1 (it) | 2002-04-19 | 2002-04-19 | Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ITTO20020340A0 true ITTO20020340A0 (it) | 2002-04-19 |
| ITTO20020340A1 ITTO20020340A1 (it) | 2003-10-20 |
Family
ID=27639017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT2002TO000340A ITTO20020340A1 (it) | 2002-04-19 | 2002-04-19 | Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato. |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20040110239A1 (it) |
| EP (1) | EP1357132A3 (it) |
| IT (1) | ITTO20020340A1 (it) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102580084B (zh) | 2005-01-21 | 2016-11-23 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
| EP1850874B1 (en) | 2005-02-23 | 2013-10-16 | Genentech, Inc. | Extending time to disease progression or survival in ovarian cancer patients using pertuzumab |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
| SI2132573T1 (sl) | 2007-03-02 | 2014-07-31 | Genentech, Inc. | Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3 |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| PL2171090T3 (pl) | 2007-06-08 | 2013-09-30 | Genentech Inc | Markery ekspresji genów odporności guza na leczenie hamujące HER2 |
| CA2713137C (en) | 2008-01-25 | 2017-10-24 | Hadasit Medical Research Services And Development Ltd. | Targeting of innate immune response to tumor site |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| MY152068A (en) | 2009-03-20 | 2014-08-15 | Genentech Inc | Bispecific anti-her antibodies |
| CN102421448A (zh) | 2009-05-29 | 2012-04-18 | 霍夫曼-拉罗奇有限公司 | Her2信号传导调控剂在表达her2的胃癌患者中 |
| US9556249B2 (en) | 2010-02-18 | 2017-01-31 | Genentech, Inc. | Neuregulin antagonists and use thereof in treating cancer |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| WO2012069466A1 (en) | 2010-11-24 | 2012-05-31 | Novartis Ag | Multispecific molecules |
| SG191153A1 (en) | 2010-12-23 | 2013-07-31 | Hoffmann La Roche | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| MX2014001766A (es) | 2011-08-17 | 2014-05-01 | Genentech Inc | Anticuerpos de neuregulina y sus usos. |
| US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
| BR112014012979A2 (pt) | 2011-11-30 | 2020-10-20 | Genentech, Inc. | mutações erbb3 em câncer |
| US9376715B2 (en) | 2011-12-09 | 2016-06-28 | Roche Molecular Systems, Inc | Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene |
| US20130259867A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
| KR102291355B1 (ko) | 2012-11-30 | 2021-08-19 | 에프. 호프만-라 로슈 아게 | Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법 |
| US20190151346A1 (en) | 2016-05-10 | 2019-05-23 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5783404A (en) * | 1995-04-13 | 1998-07-21 | Amgen Inc. | Methods and compositions for determining HER-2/neu expression using monoclonal antibodies |
| CN100340575C (zh) * | 1999-06-25 | 2007-10-03 | 杰南技术公司 | 人源化抗ErbB2抗体及其在制备药物中的应用 |
| MXPA02000962A (es) * | 1999-07-29 | 2002-07-02 | Medarex Inc | Anticuerpos monoclonales humanos para her2/neu. |
-
2002
- 2002-04-19 IT IT2002TO000340A patent/ITTO20020340A1/it unknown
-
2003
- 2003-04-16 EP EP03008916A patent/EP1357132A3/en not_active Withdrawn
- 2003-04-17 US US10/417,336 patent/US20040110239A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1357132A2 (en) | 2003-10-29 |
| ITTO20020340A1 (it) | 2003-10-20 |
| US20040110239A1 (en) | 2004-06-10 |
| EP1357132A3 (en) | 2003-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ITTO20020340A0 (it) | Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato. | |
| LT3421498T (lt) | Monokloniniai antikūnai prieš klaudiną-18, skirti vėžio gydymui | |
| EP3929214A4 (en) | ANTIBODY OR CHIMERIC ANTIGEN RECEPTOR DIRECTED AGAINST CLAUDIN 18.2 | |
| ATE545656T1 (de) | Humanisierte antikörper, die beta amyloid-peptid erkennen | |
| LTC2567976I2 (lt) | Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui | |
| NL1027975A1 (nl) | Antilichamen tegen MAdCAM. | |
| CY2012019I1 (el) | Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20 | |
| IL243914A0 (en) | Antibodies against vegf | |
| DK2019840T3 (da) | Antagonist anti-human CD40 monoklonalt antistof. | |
| NL1027009A1 (nl) | Antilichamen tegen M-CSF. | |
| CR9253A (es) | Fijacion de la dosificacion de anticuerpos her | |
| IL165193A0 (en) | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency | |
| ITRM20040362A1 (it) | Sistema per la realizzazione di costruzioni complesse. | |
| NO20054351D0 (no) | Monoklonalt antistoff og hybridom som produserer dette | |
| NO20053400D0 (no) | Fremgangsmate for fremstilling av etylenoksid. | |
| EP1461001A4 (en) | ASSOCIATED WITH CANCER EPITOP | |
| BRPI0509495A2 (pt) | anticorpo humanizado | |
| FI20020807A0 (fi) | Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita | |
| ES1058780Y (es) | Brida de union autoblocante. | |
| ATE535259T1 (de) | Immunogener, monoklonaler antikörper | |
| EP2087103A4 (en) | Cancerous disease modifying antibodies | |
| ITMO20030359A1 (it) | Sistema per produrre un materiale scorrevole. | |
| AU2003236346A1 (en) | Monoclonal antibody neutralizing megsin | |
| ITMI20022132A1 (it) | Dispositivo per la produzione di un velo cucito. | |
| ZA200906225B (en) | Cancer disease modifying antibody 010207-01 produced by hybridoma cell line AR51A630.3 |